Breaking News Instant updates and real-time market news.

BBY

Best Buy

$39.19

0.855 (2.23%)

, STX

Seagate

$35.10

-2.87 (-7.56%)

09:55
10/12/16
10/12
09:55
10/12/16
09:55

Early notable gainers among liquid option names on October 12th

Notable gainers among liquid option names this morning include Best Buy (BBY) $39.65 +1.31, Seagate (STX) $35.77 +0.68, Bristol Myers Squibb (BMY) $50.50 +0.95, Newell Rubbermaid (NWL) $51.28 +0.94, and Netflix (NFLX) $102.37 +1.78.

BBY

Best Buy

$39.19

0.855 (2.23%)

STX

Seagate

$35.10

-2.87 (-7.56%)

BMY

Bristol-Myers

$50.02

0.47 (0.95%)

NWL

Newell Brands

$50.98

0.64 (1.27%)

NFLX

Netflix

$100.59

-2.74 (-2.65%)

  • 17

    Oct

  • 19

    Oct

  • 27

    Oct

  • 28

    Oct

  • 31

    Oct

  • 06

    Nov

  • 29

    Nov

BBY Best Buy
$39.19

0.855 (2.23%)

08/24/16
DBAB
08/24/16
NO CHANGE
Target $41
DBAB
Hold
Best Buy price target raised to $41 from $32 at Deutsche Bank
Deutsche Bank analyst Mike Baker attributes Best Buy's better than expected comparable sales to share gains, which are likely due to leveraging its scale to form strong vendor partnerships, but he also notes that most indicators keep pointing to a weak consumer electronics industry. Baker raised his price target on Best Buy shares to $41 from $32 but keeps a Hold rating on the stock.
08/24/16
WEDB
08/24/16
NO CHANGE
WEDB
Best Buy likely to return to comp sales declines, says Wedbush
Wedbush analyst Michael Pachter says that Best Buy's Q2 results were bolstered by the company's control of promotional activity and by its share repurchases. However, the analyst expects the company's comps to begin to decline persistently due to "a lack of compelling new products" for the holiday season. He thinks that the company's cost cutting is approaching its limit, and he keeps an Underperform rating on the shares.
10/12/16
RHCO
10/12/16
NO CHANGE
RHCO
Best Buy, GameStop should be able to sidestep Note 7 impact, says SunTrust
SunTrust analyst David Magee, in two separate notes to investors, said that he believes Samsung's (SSNLF) troubles with the Galaxy Note 7 should not translate to shortfalls for either GameStop's (GME) mobile stores or for Best Buy (BBY), as in both cases most of their customers will simply pick different models. Sony's VR headset and other upcoming products in the category are "ideal for customers to try out in stores," added Magee, who keeps a Buy rating on both GameStop and Best Buy.
10/12/16
CLVD
10/12/16
NO CHANGE
CLVD
Neutral
Best Buy's near-term fundamentals attractive, says Cleveland Research
Cleveland Research analyst Daryle Boehringer said his near-term outlook for Best Buy is more positive given sustained share gains and increased optimistic feedback in the mobile category, creating a more attractive setup for Q3 quarter-to-date and potentially for Q4 as well. Boehringer expects domestic comps to increase 1.8%, above consensus of 1%, due to sustainability of share gains and a favorable mobile segment outlook. The analyst sees upside to his Q3 earnings estimate of 50c, versus consensus of 47c. Boehringer rates Best Buy a Neutral.
STX Seagate
$35.10

-2.87 (-7.56%)

10/11/16
10/11/16
UPGRADE
Target $43

Strong Buy
Follow-up: Seagate upgraded to Strong Buy from Buy at Needham
As previously reported, Needham upgraded Seagate to Strong Buy and raised its price target to $43 from $39. Analyst Richard Kugele said Seagate is benefiting from a generally stable to improving demand environment at the very time the company is restructuring its capacity and OPEX model for the changing environment dominated by CSPs and high-capacity drives. He believes investors will be beneficiaries of these dynamics as they flow through Seagate's model
10/12/16
BMUR
10/12/16
NO CHANGE
Target $50
BMUR
Buy
Seagate gross margin model remains underappreciated, says Brean Capital
Brean Capital analyst Ananda Baruah believes the Street is underestimating Seagate's gross margin model. The analyst also said Seagate is ahead of schedule for getting back to delivering normalized earnings, free cash flow generation, and duopoly characteristics. Baruah reiterated his Buy rating and raised his price target to $50 from $42 on Seagate shares.
10/11/16
BNCH
10/11/16
UPGRADE
BNCH
Buy
Seagate upgraded to Buy from Hold at Benchmark
10/11/16
BTIG
10/11/16
NO CHANGE
BTIG
Seagate weakness a buying opportunity, says BTIG
BMY Bristol-Myers
$50.02

0.47 (0.95%)

09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
NWL Newell Brands
$50.98

0.64 (1.27%)

09/14/16
JEFF
09/14/16
NO CHANGE
Target $66
JEFF
Buy
Newell Brands remains a top pick at Jefferies
Jefferies analyst Kevin Grundy says his regional market analysis suggests that Yankee Candle can double sales to $2B over the next six-to-seven years. He believes shares of Newell Brands remain undervalued and expects consensus estimates to move higher. The analyst calls the stock a top pick with a Buy rating and $66 price target.
08/01/16
MSCO
08/01/16
NO CHANGE
MSCO
Overweight
Newell Brands reiterated as a Top pIck at Morgan Stanley
Morgan Stanley analyst Dara Mohsenian said Newell Brands' valuation does not reflect growth opportunities post the Jarden deal. The analyst believes Newall's market share gains are sustainable and sees substantial earnings upside for the combined entity. Mohsenian reiterates Newall as an Overweight and Top Pick with plenty of room for multiple expansion.
08/01/16
UBSW
08/01/16
NO CHANGE
Target $59
UBSW
Buy
Newell Brands investor concerns over growth abating, says UBS
UBS said as Newell Brands investors concerns abate, their attention will turn to the long-term. The firm tweaked its growth forecast but raised its earnings forecast to reflect the company's underlying strength, better margin mix, and sales leverage benefits. UBS reiterated its Buy rating and raised its price target to $59 from $55 on Newell Brands shares.
10/12/16
RBCM
10/12/16
NO CHANGE
RBCM
Top Pick
Newell should be able to offset dilution from Tools sale, says RBC Capital
RBC Capital analyst Nik Modi said the EPS dilution from Newell Brands' (NWL) sale of its Tools business to Stanley Black & Decker (SWK) came in slightly ahead of his expectations, but he believes Newell will be more than able to offset this through accelerated synergy realization and/or strategic, bolt-on M&A. Modi, who believes Newell ultimately can achieve up to $750M in synergies, keeps a Top Pick rating on Newell shares.
NFLX Netflix
$100.59

-2.74 (-2.65%)

10/12/16
MSCO
10/12/16
NO CHANGE
Target $110
MSCO
Morgan Stanley sees 'un-grandfathering' peaking for Netflix in Q3
Morgan Stanley analyst Benjamin Swinburne believes the market expects Netflix (NFLX) to report Q3 domestic net subscriber additions that fall short of the company's 300K forecast. However, he thinks the impact of "un-grandfathering" will peak in Q3 and that the percentage of U.S. members seeing price increases will begin to fade in Q4. While acknowledging that Amazon (AMZN) continues to grow as a competitor for content and time spent, Swinburne notes that local and regional players in many markets continue to struggle. The analyst keeps an Overweight rating and $110 price target on Netflix shares.
10/12/16
UBSW
10/12/16
NO CHANGE
Target $92
UBSW
Neutral
Netflix app download showing maturity in U.S., picking up in Europe, says UBS
UBS analyst Doug Mitchelson said the firm's Evidence Lab shows Netflix app download data as reflecting maturity in the U.S. and Canada but picking up in Europe. The analyst said his confidence in 10M subscriber addition estimates is increased but he is not prepared to increase his estimates. Mitchelson does not expect Q3 results and Q4 guidance to resolve the bull/bear debate and continues to expect the shares to trade in a range. Mitchelson reiterated his Neutral rating on Netflix shares.
10/10/16
10/10/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Sell at Deutsche Bank. 2. Noble Midstream (NBLX) initiated with an Overweight at Barclays, a Hold at Deutsche Bank, an Overweight at JPMorgan, an Outperform at Baird, a Buy at Mizuho, a Buy at Citi, and an Overweight at MUFG. 3. AB InBev (BUD) reinstated with a Buy at Goldman. 4. First Solar (FSLR) initiated with a Neutral at Piper Jaffray. First Solar (FSLR) initiated with a Neutral at Piper Jaffray. 5. Molson Coors (TAP) reinstated with a Buy at Goldman and resumed with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/16
RAJA
10/10/16
NO CHANGE
Target $120
RAJA
Outperform
Netflix remains a core holding at Raymond James
Raymond James analyst Justin Patterson said his research suggests US churn peaked in Q2 and he remains comfortable with his 300k US net adds for Q3. Further, Patterson said early International cohorts generate greater than 20% contribution margin and said EBITDA and earnings upside is likely in 2017 and beyond. The analyst recommends owning shares for a profit inflection as investments peaked in 2016 and reiterates his Outperform rating and $120 price target.

TODAY'S FREE FLY STORIES

MTSI

MACOM

$47.13

1.08 (2.35%)

, AMCC

Applied Micro Circuits

$8.40

0.1 (1.20%)

07:30
12/05/16
12/05
07:30
12/05/16
07:30
Recommendations
MACOM, Applied Micro Circuits analyst commentary  »

MACOM remains a top pick…

MTSI

MACOM

$47.13

1.08 (2.35%)

AMCC

Applied Micro Circuits

$8.40

0.1 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 14

    Dec

  • 15

    Dec

NEM

Newmont Mining

$33.58

1.31 (4.06%)

, SDRL

Seadrill

$2.95

-0.13 (-4.22%)

07:30
12/05/16
12/05
07:30
12/05/16
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

NEM

Newmont Mining

$33.58

1.31 (4.06%)

SDRL

Seadrill

$2.95

-0.13 (-4.22%)

ORCL

Oracle

$38.50

-0.2 (-0.52%)

AET

Aetna

$133.49

-1.41 (-1.05%)

FE

FirstEnergy

$30.57

-0.42 (-1.36%)

LBTYA

Liberty Global

$29.67

-0.4 (-1.33%)

TOL

Toll Brothers

$29.32

0.18 (0.62%)

IRDM

Iridium

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

ITRI

Itron

$63.10

-0.7 (-1.10%)

07:28
12/05/16
12/05
07:28
12/05/16
07:28
Recommendations
Itron analyst commentary  »

Itron price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HDYN

Hyperdynamics

07:28
12/05/16
12/05
07:28
12/05/16
07:28
Hot Stocks
Hyperdynamics signs LOI with SAPETRO »

Hyperdynamics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNCE

Vince Holding

$3.90

-0.35 (-8.24%)

07:27
12/05/16
12/05
07:27
12/05/16
07:27
Upgrade
Vince Holding rating change  »

Vince Holding upgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

FL

Foot Locker

$74.23

0.55 (0.75%)

07:27
12/05/16
12/05
07:27
12/05/16
07:27
Recommendations
Foot Locker analyst commentary  »

Foot Locker price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NMBL

Nimble Storage

$7.72

0.28 (3.76%)

07:25
12/05/16
12/05
07:25
12/05/16
07:25
Recommendations
Nimble Storage analyst commentary  »

Nimble Storage can…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

AMZN

Amazon.com

$740.34

-3.31 (-0.45%)

07:25
12/05/16
12/05
07:25
12/05/16
07:25
Recommendations
Amazon.com analyst commentary  »

Amazon to continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$6.70

-0.5 (-6.94%)

07:25
12/05/16
12/05
07:25
12/05/16
07:25
Conference/Events
Trillium Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

QTNA

Quantenna Communications

$16.83

-0.18 (-1.06%)

07:24
12/05/16
12/05
07:24
12/05/16
07:24
Upgrade
Quantenna Communications rating change  »

Quantenna Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

TRIP

TripAdvisor

$46.46

-0.7 (-1.48%)

07:22
12/05/16
12/05
07:22
12/05/16
07:22
Upgrade
TripAdvisor rating change  »

TripAdvisor upgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$11.07

-0.21 (-1.86%)

07:21
12/05/16
12/05
07:21
12/05/16
07:21
Hot Stocks
Canadian Solar closes financing for solar power project in Japan »

Canadian Solar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

BA

Boeing

$152.25

-0.14 (-0.09%)

, EADSY

Airbus

$15.64

-0.26 (-1.64%)

07:19
12/05/16
12/05
07:19
12/05/16
07:19
Periodicals
Norwegian Air CEO aims to order more Boeing, Airbus aircraft, Reuters reports »

Norwegian Air Shuttle CEO…

BA

Boeing

$152.25

-0.14 (-0.09%)

EADSY

Airbus

$15.64

-0.26 (-1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$18.40

0.6 (3.37%)

07:19
12/05/16
12/05
07:19
12/05/16
07:19
Upgrade
Hi-Crush Partners rating change  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSN

Tyson Foods

$57.05

0.88 (1.57%)

07:18
12/05/16
12/05
07:18
12/05/16
07:18
Hot Stocks
Tyson Foods creates $150M venture capital fund »

As part of its commitment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SNSS

Sunesis

$3.90

-0.06 (-1.52%)

07:18
12/05/16
12/05
07:18
12/05/16
07:18
Hot Stocks
Sunesis says SNS-062 on track to begin dosing in Phase 1B/2 trial in 1H17 »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLT

Hilton

$25.26

0.05 (0.20%)

07:18
12/05/16
12/05
07:18
12/05/16
07:18
Hot Stocks
Hilton board approves 1-for-3 reverse stock split; sees spinoff completed Jan. 3 »

Hilton Worldwide Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TGLS

Tecnoglass

$11.81

-0.1 (-0.84%)

07:17
12/05/16
12/05
07:17
12/05/16
07:17
Hot Stocks
Tecnoglass to acquire Florida-based E.S. Windows in $13M transaction »

Tecnoglass announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

07:16
12/05/16
12/05
07:16
12/05/16
07:16
Recommendations
Alnylam analyst commentary  »

Alnylam's fitusiran…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVAX

Dynavax

$4.70

0.35 (8.05%)

07:15
12/05/16
12/05
07:15
12/05/16
07:15
Hot Stocks
Dynavax presents clinical data from SD-101 at ASH meeting »

Dynavax Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

07:15
12/05/16
12/05
07:15
12/05/16
07:15
Recommendations
Spark Therapeutics analyst commentary  »

Spark may be pressured…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ONTX

Onconova

$2.62

-0.23 (-8.07%)

07:14
12/05/16
12/05
07:14
12/05/16
07:14
Hot Stocks
Onconova presents Phase 2 data from rigosertib/azacitidine combination »

Onconova Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

F

Ford

$12.24

-0.19 (-1.53%)

07:14
12/05/16
12/05
07:14
12/05/16
07:14
Periodicals
Ford still moving small-car production to Mexico, WSJ reports »

Ford Motor is still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Jan

  • 10

    Jan

GLOG

GasLog

$15.95

0.45 (2.90%)

, GLOP

GasLog Partners

$20.60

-0.05 (-0.24%)

07:14
12/05/16
12/05
07:14
12/05/16
07:14
Hot Stocks
GasLog announces order of FSRU LLIs »

GasLog (GLOG) announces…

GLOG

GasLog

$15.95

0.45 (2.90%)

GLOP

GasLog Partners

$20.60

-0.05 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

VBLT

VBL Therapeutics

$5.25

0.05 (0.96%)

07:13
12/05/16
12/05
07:13
12/05/16
07:13
Hot Stocks
VBL says DSMC recommends Phase 3 GLOBE study continue as planned »

VBL Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.